In chapter 4, industry thought leaders explore how polygenic risk scores will one day impact clinical care—as early predictors of disease, when there is an unclear diagnosis, and early detection of cancer are a few possible applications. Hear from Professor of Statistical Genetics David Evans, Professor of Quantitative Genetics Peter Visscher, Geneticist Gerome Breen, Professor of Psychiatric and Quantitative Genetics Naomi Ray, and Representative Director of Genome Analytics Japan Co., Ltd. Tsuyoshi Hachiya.
Subscribe to the Illumina video channel [ Ссылка ]
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Illumina technology is responsible for generating more than 90% of the world’s sequencing data.* Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
*Data calculations on file. Illumina, Inc., 2015.
View customer spotlight videos
[ Ссылка ]
View Illumina webinars
[ Ссылка ]
View Illumina product videos
[ Ссылка ]
View Illumina support videos
[ Ссылка ]
